INTRA-ARTERIAL MeVO TREATMENT (IMP-ACT) Within the ACT-GLOBAL Adaptive Platform Trial-NCT06352632

A phase 3 trial registered on ClinicalTrials.gov. The registry status is not yet recruiting. It plans to enroll 800 participants.

Also called NCT07906275

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; single masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 800 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT07906275
Planned start
(anticipated) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
Canada (from the registry)
Registry status
  • Not yet recruiting (from the registry)

Technical summary

Registry record NCT07906275. Randomized; single masking; primary purpose treatment. Start 2026-12-15 (anticipated); primary completion 2030-12-31 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
INTRA-ARTERIAL MeVO TREATMENT (IMP-ACT) Within the ACT-GLOBAL Adaptive Platform Trial-NCT06352632
Acronym
IMP-ACT
Condition
Stroke, Acute Ischemic
Condition
Medium Vessel Occlusion
Intervention (Procedure)
Mechanical Endovascular Thrombectomy
Intervention (Drug)
Intravenous Thrombolysis
Intervention (Biological)
Tenecteplase/Alteplase- depending upon availability at each treating centre
Lead sponsor
University of Calgary (class: other)
Collaborator
The George Institute for Global Health, Australia (class: other)

Record details

Record id
cardio:ct-nct07906275
Content hash
7f26cbe651c86a5ec2e9495d665389ee71159c944ca6d2eb4c2a4b97f372cea5